Theravance Biopharma (TBPH) Projected to Post Quarterly Earnings on Monday

Theravance Biopharma (NASDAQ:TBPH) is anticipated to announce its Q3 2025 results after the market closes on Monday, November 10th. Analysts expect Theravance Biopharma to post earnings of ($0.03) per share and revenue of $19.8940 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Monday, November 10, 2025 at 5:00 PM ET.

Theravance Biopharma Stock Performance

NASDAQ:TBPH opened at $14.75 on Friday. The company has a 50-day moving average of $14.20 and a 200-day moving average of $12.06. Theravance Biopharma has a 52 week low of $7.90 and a 52 week high of $15.34. The company has a market capitalization of $742.81 million, a price-to-earnings ratio of 61.46 and a beta of 0.07.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TBPH. B. Riley started coverage on shares of Theravance Biopharma in a research note on Friday, September 12th. They set a “buy” rating and a $28.00 price target for the company. Wall Street Zen upgraded Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 16th. Zacks Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 15th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Theravance Biopharma in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $23.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC grew its holdings in Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 781 shares during the period. AQR Capital Management LLC bought a new stake in Theravance Biopharma in the first quarter valued at about $101,000. Creative Planning acquired a new position in Theravance Biopharma in the second quarter valued at about $139,000. Engineers Gate Manager LP acquired a new position in Theravance Biopharma in the second quarter valued at about $151,000. Finally, Oxford Asset Management LLP bought a new position in Theravance Biopharma during the second quarter worth about $159,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.